Page 1310 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 90

REFERENCES

1. Arnold DM, Donahoe L, Clarke FJ, et al. Bleeding during 13. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa
critical illness: a prospective cohort study using a new measure- (activated) in adults with septic shock. N Engl J Med. May 31,
ment tool. Clinical and investigative medicine. Clin Invest Med. 2012;366(22):2055-2064.
2007;30(2):E93-E102. 14. Warren BL, Eid A, Singer P, et al. Caring for the critically ill
2. Walsh TS, Stanworth SJ, Prescott RJ, et al. Prevalence, manage- patient. High-dose antithrombin III in severe sepsis: a random-
ment, and outcomes of critically ill patients with prothrombin ized controlled trial. JAMA. October 17, 2001;286(15):1869-1878.
time prolongation in United Kingdom intensive care units. Crit 15. Levi M, Schultz M, van der Poll T. Coagulation biomarkers in
Care Med. October 2010;38(10):1939-1946. critically ill patients. Crit Care Clin. April 2011;27(2):281-297.
3. Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement 16. Drake TA, Cheng J, Chang A, Taylor FB. Expression of tissue
of bleeding severity: a critical review. Transfusion. April factor, thrombomodulin, and E-selectin in baboons with lethal
2004;44(4):605-617. Escherichia-coli sepsis. Am J Pathol. May 1993;142(5):1458-1470.
4. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting 17. Faust SN, Heyderman RS, Levin M. Coagulation in severe sep-
results of cancer treatment. Cancer. January 1, 1981;47(1): sis: a central role for thrombomodulin and activated protein C.
207-214. Crit Care Med. July 2001;29(7 suppl):S62-67; discussion S67-68.
5. Lauzier F, Arnold DM, Rabbat C, et al. Risk factors and 18. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothe-
impact of major bleeding in critically ill patients receiving lial protein C activation in severe meningococcal sepsis. N Engl
heparin thromboprophylaxis. Intensive Care Med. December J Med. August 9, 2001;345(6):408-416.
2013;39(12):2135-2143. 19. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasmino-
6. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleed- gen into plasmin at the surface of endothelial microparticles:
ing severity index: validation and comparison to other methods a mechanism that modulates angiogenic properties of endo-
for classifying bleeding complications of medical therapy. J Clin thelial progenitor cells in vitro. Blood. October 1, 2007;110(7):
Epidemiol. 1989;42(8):711-718. 2432-2439.
7. Brown RB, Klar J, Teres D, Lemeshow S, Sands M. Prospective 20. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie
study of clinical bleeding in intensive care unit patients. Crit BC. Glycoprotein VI-dependent and -independent pathways
Care Med. December 1988;16(12):1171-1176. of thrombus formation in vivo. Blood. May 15, 2006;107(10):
8. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission 3902-3906.
associated with bleeding risk in medical patients: findings from 21. Massberg S, Gawaz M, Gruner S, et al. A crucial role of glyco-
the IMPROVE investigators. Chest. January 2011;139(1):69-79. protein VI for platelet recruitment to the injured arterial wall in
9. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastroin- vivo. Journal Exp Med. January 6, 2003;197(1):41-49.
testinal bleeding in critically ill patients. Canadian Critical Care 22. Ruggeri ZM. Old concepts and new developments in the
Trials Group. N Engl J Med. February 10, 1994;330(6):377-381. study of platelet aggregation. J Clin Invest. March 2000;105(6):
699-701.
10. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook
DJ. Heparin thromboprophylaxis in medical-surgical critically 23. Robertson J, Lillicrap D, James PD. Von Willebrand disease.
ill patients: a systematic review and meta-analysis of random- Pediatr Clin North Am. April 2008;55(2):377-392, viii-ix.
ized trials. Crit Care Med. September 2013;41(9):2088-2098. 24. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective plate-
11. Haase N, Wetterslev J, Winkel P, Perner A. Bleeding and risk of let activation in G alpha(q)-deficient mice. Nature. September
death with hydroxyethyl starch in severe sepsis: post hoc analy- 11, 1997;389(6647):183-186.
ses of a randomized clinical trial. Intensive Care Med. December 25. Jackson SP. The growing complexity of platelet aggregation.
2013;39(12):2126-2134. Blood. June 15, 2007;109(12):5087-5095.
12. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety 26. van der Poll T, de Boer JD, Levi M. The effect of inflammation
of recombinant human activated protein C for severe sepsis. on coagulation and vice versa. Curr Opin Infect Dis. June 2011;
N Engl J Med. March 8, 2001;344(10):699-709. 24(3):273-278.

Section07-O-ref.indd 1 1/21/2015 11:26:47 AM